ReviewCancer drug resistance (Alhambra, Calif.)2020
Why nanodiamond carriers manage to overcome drug resistance in cancer.
Review in Cancer drug resistance (Alhambra, Calif.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of nanocarriers used in medicine and beyond - definition and categorization framework.Journal of nanobiotechnology · 2025Pooled it
- From Nature to Medicine: Overcoming the Limitations of Herbal Therapeutics for Pancreatic Cancer Treatment Based on Nanotechnology.Nanomaterials (Basel, Switzerland) · 2026Review
- Multifunctional Nanodiamond Conjugate With a Tumor-Specific EGFR-Targeting Peptide and Photoactivated CO Release for Improved Therapeutic Efficacy in Head and Neck Cancers.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Silk Fibroin for Biomedical Applications with Emphasis on Bioimaging, Biosensing and Regenerative Systems: A Review.Molecules (Basel, Switzerland) · 2026Review
- Efficientand Robust Automated Segmentation of Nanoparticles and Aggregates from Transmission Electron Microscopy Images with Highly Complex Backgrounds.Nanomaterials (Basel, Switzerland) · 2024Article
- Nanodiamonds: Next generation nano-theranostics for cancer therapy.Cancer letters · 2024Review
- Complex Dispersion of Detonation Nanodiamond Revealed by Machine Learning Assisted Cryo-TEM and Coarse-Grained Molecular Dynamics Simulations.ACS nanoscience Au · 2023Article
- Multiple Bioimaging Applications Based on the Excellent Properties of Nanodiamond: A Review.Molecules (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanodiamonds represent an attractive potential carrier for anticancer drugs. The main advantages of nanodiamond particles with respect to medical applications are their high compatibility with non-cancerous cells, feasible surface decoration with therapeutic and cancer-cell targeting molecules, and their relatively low manufacturing cost. Additionally, nanodiamond carriers significantly increase treatment efficacy of the loaded drug, so anticancer drugs execute more effectively at a lower dose. Subsequently, lower drug dose results in less extensive side effects. The carriers decorated with a targeting molecule accumulate primarily in the tumor tissue, and those nanodiamond particles impair efflux of the drug from cancer cells. Therapeutic approaches considering nanodiamond carriers were already tested
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.